Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0) has announced a significant overhaul of its Board of Directors, appointing four new members and accepting the resignations of three others, effective September 28, 2026. The changes, disclosed in a press release, are part of an ongoing board renewal strategy to bolster governance and expertise as the clinical-stage oncology company advances its pipeline for difficult-to-treat cancers.
The new appointees are Karen Krumeich, Jamieson Bondarenko, CFA, CMT, Charmaine Lykins, MBA, and Dirk Brockstedt, Ph.D. Ms. Krumeich has also been appointed Chair of the Board and Audit Committee. Concurrently, Jacek Antas, Malgorzata Laube, and Jerzy Leszczynski have voluntarily resigned from the Board to facilitate the transition.
“We are very pleased to welcome Karen, Jamieson, Charmaine and Dirk to Helix’s Board,” said Thomas Mehrling, M.D., Ph.D., Chief Executive Officer of Helix BioPharma. “Together, these Board members bring an exceptional breadth of complementary expertise across biotechnology leadership, scientific and clinical development, capital markets, corporate governance, and commercialization. Their collective experience significantly strengthens our Board at an important stage in Helix’s evolution. We believe their strategic insight, industry relationships and proven leadership will be invaluable as we advance our oncology pipeline, execute our strategic objectives, and position Helix for sustainable, long-term value creation for our shareholders.” Dr. Mehrling also extended gratitude to the departing directors for their service.
The appointments bring deep and diverse experience. Karen Krumeich is a life sciences financial executive who has served as CFO and EVP for public and private companies, including Kazia Therapeutics, TheraVectys, and Soligenix. She currently serves as fractional CFO with the Lisa Stone Group and as Managing Director of Golden Seeds. Jamieson Bondarenko is an active investor and capital markets executive, currently Chairman of the Board of BriaCell Therapeutics Corp. and a capital markets advisor to MustGrow Biologics Corp. Charmaine Lykins is a biopharmaceutical executive with over 30 years in commercial strategy and product launches, currently CEO of Transneural Therapeutics. Dirk Brockstedt, Ph.D., is a biotechnology executive and scientist with more than 25 years in research and clinical development, previously CSO of RAPT Therapeutics and EVP of R&D at Aduro BioTech.
Following these changes, the Board comprises six directors, four of whom are independent. The Audit Committee has been reconstituted with independent directors Karen Krumeich as Chair, Zachary T. Stadnyk, and Jamieson Bondarenko.
“I am honored to join Helix as Chair at an important stage in the Company’s development,” said Karen Krumeich, Chair of the Board. “The Board brings together complementary scientific, commercial, financial and capital markets expertise, and I look forward to working with Thomas and the management team as Helix advances its pipeline and executes on its strategic priorities.”
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company’s common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCF), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit https://www.helixbiopharma.com/. The original release is available on www.newmediawire.com, and the company’s periodic reports are filed on SEDAR+ at www.sedarplus.ca.
